GLA gene therapy (Viltagen BioPharma)

N/A

Report date: 2025/06/11 10:53:44

Base Information

Drug NameGLA gene therapy (Viltagen BioPharma)
Drug Alias NameAAV8-P18-M7AAV8-P14-M7
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of Actionα-Galactosidase stimulants
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Vitalgen BioPharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Vitalgen BioPharma Co Ltd
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A